{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:37:19Z","timestamp":1791005839534,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1038\/ncpgasthep0359","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T11:19:50Z","timestamp":1133781590000},"page":"580-586","source":"Crossref","is-referenced-by-count":123,"title":["The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases"],"prefix":"10.1038","volume":"2","author":[{"given":"S\u00e9verine","family":"Vermeire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpgasthep0359_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMe048020","volume":"350","author":"AR Tall","year":"2004","unstructured":"Tall AR (2004) C-reactive protein reassessed. N Engl J Med 350: 1450\u20131452","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR2","first-page":"283","volume-title":"Immunology of the Gut","author":"MB Pepys","year":"1977","unstructured":"Pepys MB et al. (1977) Immunological studies in inflammatory bowel disease. In: Immunology of the Gut, Ciba Foundation Symposium 283\u2013297 (Eds Porter R and Knight J). Amsterdam: Elsevier\/Excerpta Medica"},{"key":"BFncpgasthep0359_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI116336","volume":"91","author":"DM Vigushin","year":"1993","unstructured":"Vigushin DM et al. (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351\u20131357","journal-title":"J Clin Invest"},{"key":"BFncpgasthep0359_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/gut.27.7.809","volume":"27","author":"SH Saverymuttu","year":"1986","unstructured":"Saverymuttu SH et al. (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 27: 809\u2013813","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00001574-200407000-00003","volume":"20","author":"G Rogler","year":"2004","unstructured":"Rogler G (2004) Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 20: 311\u2013317","journal-title":"Curr Opin Gastroenterol"},{"key":"BFncpgasthep0359_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/0016-5085(92)90098-J","volume":"102","author":"V Gross","year":"1992","unstructured":"Gross V et al. (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102: 514\u2013519","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0359_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0009-8981(85)90219-0","volume":"148","author":"B Shine","year":"1985","unstructured":"Shine B et al. (1985) C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 148: 105\u2013109","journal-title":"Clin Chim Acta"},{"key":"BFncpgasthep0359_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/adc.73.4.354","volume":"73","author":"RM Beattie","year":"1995","unstructured":"Beattie RM et al. (1995) Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73: 354\u2013355","journal-title":"Arch Dis Child"},{"key":"BFncpgasthep0359_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00042737-200204000-00013","volume":"14","author":"AP Poullis","year":"2002","unstructured":"Poullis AP et al. (2002) A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 14: 409\u2013412","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0359_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","volume":"12","author":"EA Fagan","year":"1982","unstructured":"Fagan EA et al. (1982) Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 12: 351\u2013359","journal-title":"Eur J Clin Invest"},{"key":"BFncpgasthep0359_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.22.7.571","volume":"22","author":"C Andre","year":"1981","unstructured":"Andre C et al. (1981) Assessment of appropriate laboratory measurements to supplement the Crohn's disease acitivity index. Gut 22: 571\u2013574","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3109\/00365529209011182","volume":"27","author":"A Tromm","year":"1992","unstructured":"Tromm A et al. (1992) Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 27: 774\u2013778","journal-title":"Scand J Gastroenterol"},{"key":"BFncpgasthep0359_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0753-3322(96)82632-1","volume":"49","author":"G Ricci","year":"1995","unstructured":"Ricci G et al. (1995) Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother 49: 259\u2013262","journal-title":"Biomed Pharmacother"},{"key":"BFncpgasthep0359_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem CA et al. (2005) Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis 11: 707\u2013712","journal-title":"Inflamm Bowel Dis"},{"key":"BFncpgasthep0359_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0733-8651(03)00079-1","volume":"21","author":"PM Ridker","year":"2003","unstructured":"Ridker PM and Morrow DA (2003) C-reactive protein, inflammation, and coronary risk. Cardiol Clin 21: 315\u2013325","journal-title":"Cardiol Clin"},{"key":"BFncpgasthep0359_CR16","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1056\/NEJMoa032804","volume":"350","author":"J Danesh","year":"2004","unstructured":"Danesh J et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387\u20131397","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","volume":"80","author":"R Bataille","year":"1992","unstructured":"Bataille R et al. (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733\u2013737","journal-title":"Blood"},{"key":"BFncpgasthep0359_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00004836-198808000-00011","volume":"10","author":"M Boirivant","year":"1988","unstructured":"Boirivant M et al. (1988) The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10: 401\u2013405","journal-title":"J Clin Gastroenterol"},{"key":"BFncpgasthep0359_CR19","first-page":"A53","volume-title":"Gastroenterology","author":"Y Consigny","year":"2001","unstructured":"Consigny Y et al. (2001) Biological markers of short term relapse in Crohn's disease (CD) [Abstract]. Gastroenterology 20 (Suppl): A53"},{"key":"BFncpgasthep0359_CR20","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/0016-5085(86)90206-4","volume":"91","author":"C Brignola","year":"1986","unstructured":"Brignola C et al. (1986) A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 91: 1490\u20131494","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0359_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP et al. (1996) Predicting outcome in severe ulcerative colitis. Gut 38: 905\u2013910","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029\u20131035","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398\u20131405","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR24","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541\u20131549","journal-title":"Lancet"},{"key":"BFncpgasthep0359_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876\u2013885","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR26","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","volume":"37","author":"E Louis","year":"2002","unstructured":"Louis E et al. (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37: 818\u2013824","journal-title":"Scand J Gastroenterol"},{"key":"BFncpgasthep0359_CR27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1136\/gut.2003.035253","volume":"53","author":"WJ Sandborn","year":"2004","unstructured":"Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485\u20131493","journal-title":"Gut"},{"issue":"Suppl","key":"BFncpgasthep0359_CR28","first-page":"A215","volume":"52","author":"S Schreiber","year":"2003","unstructured":"Schreiber S et al. (2003) Safety of CDP870, a pegylated humanized anti-TNF antibody fragment in Crohn's disease [Abstract]. Gut 52 (Suppl): A215","journal-title":"Gut"},{"issue":"Suppl","key":"BFncpgasthep0359_CR29","first-page":"A239","volume":"52","author":"P Rutgeerts","year":"2003","unstructured":"Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02925968","volume":"25","author":"C Dervenis","year":"1999","unstructured":"Dervenis C et al. (1999) Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol 25: 195\u2013210","journal-title":"Int J Pancreatol"},{"key":"BFncpgasthep0359_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/bjs.1800760224","volume":"76","author":"C Wilson","year":"1989","unstructured":"Wilson C et al. (1989) C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 76: 177\u2013181","journal-title":"Br J Surg"},{"key":"BFncpgasthep0359_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/gut.33.9.1264","volume":"33","author":"JA Viedma","year":"1992","unstructured":"Viedma JA et al. (1992) Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 33: 1264\u20131267","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02795248","volume":"1","author":"M Buchler","year":"1986","unstructured":"Buchler M et al. (1986) Sensitivity of antiproteases, complement factors and C-reactive protein in detecting pancreatic necrosis. Results of a prospective clinical study. Int J Pancreatol 1: 227\u2013235","journal-title":"Int J Pancreatol"},{"key":"BFncpgasthep0359_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000070079","volume":"3","author":"J Werner","year":"2003","unstructured":"Werner J et al. (2003) Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 3: 115\u2013127","journal-title":"Pancreatology"},{"key":"BFncpgasthep0359_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/gut.28.6.764","volume":"28","author":"P Puolakkainen","year":"1987","unstructured":"Puolakkainen P et al. (1987) C -reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 28: 764\u2013771","journal-title":"Gut"},{"key":"BFncpgasthep0359_CR36","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/S0140-6736(00)02317-5","volume":"355","author":"JA Windsor","year":"2000","unstructured":"Windsor JA (2000) Search for prognostic markers for acute pancreatitis. Lancet 355: 1924\u20131925","journal-title":"Lancet"},{"key":"BFncpgasthep0359_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/bjs.1800820244","volume":"82","author":"H Paajanen","year":"1995","unstructured":"Paajanen H et al. (1995) Serum tumour necrosis factor compared with C-reactive protein in the early assessment of severity of acute pancreatitis. Br J Surg 82: 271\u2013273","journal-title":"Br J Surg"},{"key":"BFncpgasthep0359_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF01537230","volume":"35","author":"V Gross","year":"1990","unstructured":"Gross V et al. (1990) Granulocyte elastase in assessment of severity of acute pancreatitis. Comparison with acute-phase proteins C-reactive protein, alpha 1-antitrypsin, and protease inhibitor alpha 2-macroglobulin. Dig Dis Sci 35: 97\u2013105","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0359_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/145749690209100408","volume":"91","author":"MT Hamalainen","year":"2002","unstructured":"Hamalainen MT et al. (2002) Do normal leukocyte count and C-reactive protein on admission to hospital exclude a life-threatening attack of acute pancreatitis? Scand J Surg 91: 353\u2013356","journal-title":"Scand J Surg"},{"key":"BFncpgasthep0359_CR40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s005350200157","volume":"37","author":"T Imamura","year":"2002","unstructured":"Imamura T et al. (2002) Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J Gastroenterol 37: 935\u2013938","journal-title":"J Gastroenterol"},{"key":"BFncpgasthep0359_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1155\/1994\/69467","volume":"8","author":"H Kiviniemi","year":"1994","unstructured":"Kiviniemi H et al. (1994) Acute phase response in patients with uncomplicated and complicated endoscopic retrogradic cholangiopancreaticography. HPB Surg 8: 129\u2013131","journal-title":"HPB Surg"},{"key":"BFncpgasthep0359_CR42","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1023\/A:1018887704337","volume":"43","author":"M Oezcueruemez-Porsch","year":"1998","unstructured":"Oezcueruemez-Porsch M et al. (1998) Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci 43: 1763\u20131769","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0359_CR43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1067\/mge.2001.117763","volume":"54","author":"M Kaw","year":"2001","unstructured":"Kaw M and Singh S (2001) Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 54: 435\u2013440","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep0359_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","volume":"348","author":"JA Baron","year":"2003","unstructured":"Baron JA et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891\u2013899","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR45","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","volume":"328","author":"FM Giardiello","year":"1993","unstructured":"Giardiello FM et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313\u20131316","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR46","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach G et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946\u20131952","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0359_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jama.291.5.585","volume":"291","author":"TP Erlinger","year":"2004","unstructured":"Erlinger TP et al. (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585\u2013590","journal-title":"JAMA"},{"key":"BFncpgasthep0359_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-142-6-200503150-00008","volume":"142","author":"SM Zhang","year":"2005","unstructured":"Zhang SM et al. (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142: 425\u2013432","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep0359_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0002-9610(98)00204-9","volume":"176","author":"T Nozoe","year":"1998","unstructured":"Nozoe T et al. (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335\u2013338","journal-title":"Am J Surg"},{"key":"BFncpgasthep0359_CR50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00042737-200304000-00006","volume":"15","author":"YC Chung","year":"2003","unstructured":"Chung YC and Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369\u2013373","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"BFncpgasthep0359_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/bjs.4038","volume":"90","author":"DC McMillan","year":"2003","unstructured":"McMillan DC et al. (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215\u2013219","journal-title":"Br J Surg"},{"key":"BFncpgasthep0359_CR52","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3748\/wjg.v11.i11.1639","volume":"11","author":"NI Nikiteas","year":"2005","unstructured":"Nikiteas NI et al. (2005) Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11: 1639\u20131643","journal-title":"World J Gastroenterol"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0359","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:01:47Z","timestamp":1684440107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["BFncpgasthep0359"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0359","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}